Subcutaneous Amivantamab Cancer Trial Shows Pro...

By HEOR Staff Writer

June 1, 2026

The Phase 1b/2 OrigAMI-4 study demonstrated that subcutaneous amivantamab and hyaluronidase-lpuj produced a confirmed overall response rate of 42 percent in patients with recurrent or metastatic head and neck squamous cell carcinoma previously tre...